Mikołaj Gołdyn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mikołaj Gołdyn has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Justyna Jusiak
Hospital The Monument of the Baptism of Poland, Gniezno, Poland
3 shared publications - Karolina Kubala
Provincial Specialist Hospital named after J. Gromkowski Ul.Koszarowa 5, 51-149 Wrocław
3 shared publications - Magdalena Grabińska
General Practice, Józef Struś Multispecialty Municipal Hospital, ul. Szwajcarska 3, 61-285 Poznań, Poland
3 shared publications - Paulina Halik
The Baptism of Poland Memorial Hospital, ul. Świętego Jana 9, 62-200 Gniezno, Poland
3 shared publications - Tomasz Pietrucha
Wrocław Medical University, Wybrzeże Ludwika Pasteura 1, 50-367 Wrocław, Poland
3 shared publications - Adam Dudek
University Hospital in Poznań Przybyszewskiego 49, 60-355 Poznań
1 shared publication
Latest Publications
- Open Access
- 3 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51, 68476
Subcutaneous versus Sublingual Allergen Immunotherapy in Allergic Rhinitis and Asthma: A Comparative Narrative Review
Allergen-specific immunotherapy (AIT) represents the only disease-modifying intervention for IgE-mediated allergic diseases, including allergic rhinitis and allergic asthma. Among the currently available administration routes, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most extensively studied and clinically implemented. Despite their widespread use, uncertainty persists regarding their relative efficacy, safety, and real-world applicability across different patient populations and allergen types. AIM: The aim of this study was to critically compare the clinical effectiveness, safety profile, and treatment adherence of SCIT and SLIT based on data derived from PubMed-indexed randomized controlled trials, systematic reviews, and meta-analyses. Material and methods: A narrative synthesis of peer-reviewed literature was conducted, focusing on studies directly or indirectly comparing SCIT and SLIT in patients with allergic rhinitis, allergic asthma, or rhinoconjunctivitis. Primary endpoints included symptom score reduction and medication use, while secondary outcomes encompassed adverse events, immunological responses, and adherence rates. Results: Both SCIT and SLIT demonstrated significant clinical efficacy compared with placebo or pharmacotherapy alone. Overall symptom reduction and medication sparing effects were largely comparable between the two modalities. SCIT showed a trend toward slightly greater efficacy in selected allergens, particularly grass pollen, whereas SLIT consistently exhibited a superior safety profile with fewer systemic adverse reactions. Conclusion: SCIT and SLIT are both effective forms of allergen immunotherapy. While SCIT may provide marginal advantages in symptom control in specific clinical contexts, SLIT offers improved safety and convenience. Treatment choice should therefore be individualized, considering patient characteristics, allergen profile, and risk tolerance.
- 3 February 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 51, 68476
Open AccessSubcutaneous versus Sublingual Allergen Immunotherapy in Allergic Rhinitis and Asthma: A Comparative Narrative Review
Allergen-specific immunotherapy (AIT) represents the only disease-modifying intervention for IgE-mediated allergic diseases, including allergic rhinitis and allergic asthma. Among the currently available administration routes, subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are the most extensively studied and clinically implemented. Despite their widespread use, uncertainty persists regarding their relative efficacy, safety, and real-world applicability across different patient populations and allergen types. AIM: The aim of this study was to critically compare the clinical effectiveness, safety profile, and treatment adherence of SCIT and SLIT based on data derived from PubMed-indexed randomized controlled trials, systematic reviews, and meta-analyses. Material and methods: A narrative synthesis of peer-reviewed literature was conducted, focusing on studies directly or indirectly comparing SCIT and SLIT in patients with allergic rhinitis, allergic asthma, or rhinoconjunctivitis. Primary endpoints included symptom score reduction and medication use, while secondary outcomes encompassed adverse events, immunological responses, and adherence rates. Results: Both SCIT and SLIT demonstrated significant clinical efficacy compared with placebo or pharmacotherapy alone. Overall symptom reduction and medication sparing effects were largely comparable between the two modalities. SCIT showed a trend toward slightly greater efficacy in selected allergens, particularly grass pollen, whereas SLIT consistently exhibited a superior safety profile with fewer systemic adverse reactions. Conclusion: SCIT and SLIT are both effective forms of allergen immunotherapy. While SCIT may provide marginal advantages in symptom control in specific clinical contexts, SLIT offers improved safety and convenience. Treatment choice should therefore be individualized, considering patient characteristics, allergen profile, and risk tolerance.
- Open Access
- 31 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Total hip arthroplasty in elderly patients: treatment-specific considerations, risk of complications, and functional outcomes
Introduction Total hip arthroplasty (THA) is a widely used and effective procedure for treating advanced hip disorders. With population aging, the number of THA procedures in elderly patients is steadily increasing. Advanced age is associated with comorbidities and reduced physiological reserve, which may influence perioperative risk and postoperative outcomes. Aim This review aimed to summarize current evidence on total hip arthroplasty in elderly patients, focusing on surgical management, perioperative care, rehabilitation, and clinical outcomes. Materials and methods A narrative review of the literature was conducted using PubMed, Scopus, and Web of Science databases. Publications between 2001 and 2025 were included. The review focused on adults aged ≥65 years and synthesized findings narratively across surgical indications and management, perioperative care, risk of complications, rehabilitation, and functional outcomes following total hip arthroplasty. Results Available evidence indicates that THA provides significant pain relief and functional improvement in elderly patients, including those aged 80 years and older. Cemented implants are associated with lower early revision rates and better implant survival in patients with poor bone quality, while uncemented and hybrid prostheses may be appropriate in selected cases. Elderly patients have a higher risk of perioperative complications, such as cardiopulmonary events, delirium, and periprosthetic fractures. Early mobilization and structured rehabilitation significantly improve functional recovery and reduce complication rates. Conclusion Total hip arthroplasty is a safe and effective treatment option for elderly patients when individualized surgical planning, comprehensive perioperative management, and multidisciplinary rehabilitation are applied. Advanced age alone should not be considered a contraindication to surgery.
- 31 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessTotal hip arthroplasty in elderly patients: treatment-specific considerations, risk of complications, and functional outcomes
Introduction Total hip arthroplasty (THA) is a widely used and effective procedure for treating advanced hip disorders. With population aging, the number of THA procedures in elderly patients is steadily increasing. Advanced age is associated with comorbidities and reduced physiological reserve, which may influence perioperative risk and postoperative outcomes. Aim This review aimed to summarize current evidence on total hip arthroplasty in elderly patients, focusing on surgical management, perioperative care, rehabilitation, and clinical outcomes. Materials and methods A narrative review of the literature was conducted using PubMed, Scopus, and Web of Science databases. Publications between 2001 and 2025 were included. The review focused on adults aged ≥65 years and synthesized findings narratively across surgical indications and management, perioperative care, risk of complications, rehabilitation, and functional outcomes following total hip arthroplasty. Results Available evidence indicates that THA provides significant pain relief and functional improvement in elderly patients, including those aged 80 years and older. Cemented implants are associated with lower early revision rates and better implant survival in patients with poor bone quality, while uncemented and hybrid prostheses may be appropriate in selected cases. Elderly patients have a higher risk of perioperative complications, such as cardiopulmonary events, delirium, and periprosthetic fractures. Early mobilization and structured rehabilitation significantly improve functional recovery and reduce complication rates. Conclusion Total hip arthroplasty is a safe and effective treatment option for elderly patients when individualized surgical planning, comprehensive perioperative management, and multidisciplinary rehabilitation are applied. Advanced age alone should not be considered a contraindication to surgery.
- Open Access
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Breast Cancer Risk in Users of Hormonal Contraception
Combined oral contraceptives (COCs) are a widely used method of birth control among women. They have a low Pearl Index, confirming high efficacy. Their mechanism of action relies on suppression of ovulation. This is achieved through the influence of estrogenic and progestogenic components on the release of follicle-stimulating hormone and luteinizing hormone from the pituitary gland. COCs also inhibit fertilization by altering cervical mucus composition and prevent blastocyst implantation. The mechanism of action of COCs allows their use for non-contraceptive purposes. For example, they reduce the risk of ovarian and endometrial cancer. They also limit menstrual bleeding and alleviate acne, migraine headaches, and dysphoric symptoms. Conversely, adverse effects of COCs include an increased risk of cervical cancer. Their impact on breast cancer remains inconclusive. Clinical studies have demonstrated that the overall incidence of breast cancer among women using COCs is comparable to that among women who have never used them. However, during COC use and shortly after discontinuation, the risk of developing breast cancer is elevated, whereas it decreases five years after cessation. Among women with BRCA1 or BRCA2 mutations, the impact of COCs remains uncertain, with some studies reporting increased risk and others suggesting a reduction. Breast cancer is the most frequently diagnosed malignancy among women and the second leading cause of cancer-related death. Prognosis is often dependent on the stage at diagnosis. Mortality risk due to breast cancer is higher among women using COCs, whereas it does not significantly change with the use of progestin-only oral contraceptives. Some patients discontinue oral contraception due to concerns about adverse effects and a potential increase in breast cancer risk. The aim of this study was to present the mechanisms of COC action within breast tissue and their influence on the risk of breast cancer.
- 27 January 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 50
Open AccessBreast Cancer Risk in Users of Hormonal Contraception
Combined oral contraceptives (COCs) are a widely used method of birth control among women. They have a low Pearl Index, confirming high efficacy. Their mechanism of action relies on suppression of ovulation. This is achieved through the influence of estrogenic and progestogenic components on the release of follicle-stimulating hormone and luteinizing hormone from the pituitary gland. COCs also inhibit fertilization by altering cervical mucus composition and prevent blastocyst implantation. The mechanism of action of COCs allows their use for non-contraceptive purposes. For example, they reduce the risk of ovarian and endometrial cancer. They also limit menstrual bleeding and alleviate acne, migraine headaches, and dysphoric symptoms. Conversely, adverse effects of COCs include an increased risk of cervical cancer. Their impact on breast cancer remains inconclusive. Clinical studies have demonstrated that the overall incidence of breast cancer among women using COCs is comparable to that among women who have never used them. However, during COC use and shortly after discontinuation, the risk of developing breast cancer is elevated, whereas it decreases five years after cessation. Among women with BRCA1 or BRCA2 mutations, the impact of COCs remains uncertain, with some studies reporting increased risk and others suggesting a reduction. Breast cancer is the most frequently diagnosed malignancy among women and the second leading cause of cancer-related death. Prognosis is often dependent on the stage at diagnosis. Mortality risk due to breast cancer is higher among women using COCs, whereas it does not significantly change with the use of progestin-only oral contraceptives. Some patients discontinue oral contraception due to concerns about adverse effects and a potential increase in breast cancer risk. The aim of this study was to present the mechanisms of COC action within breast tissue and their influence on the risk of breast cancer.